Chemotherapy of Hodgkin's disease (Q37732507)

22 August 2017

1 reference

title

Chemotherapy of Hodgkin's disease (English)

1 reference

22 August 2017

Oza AM

1

1 reference

22 August 2017

Rohatiner AZ

series ordinal

2

1 reference

22 August 2017

Lister TA

series ordinal

3

1 reference

22 August 2017

publication date

1 January 1991

1 reference

Best Practice and Research: Clinical Haematology

22 August 2017

published in

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

131-156

1 reference

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Treatment of Hodgkin's disease stages I and II with chemotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effects on sexual function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Septicemia and meningitis in children splenectomized for hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartholomew's Hospital. A retrospective review of 114 previously untreated patients over 14 years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The incidence of post-splenectomy sepsis and herpes zoster in children and adolescents with Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Female Reproductive Potential after Treatment for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Hodgkin's disease in children. A ten-year experience in South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The Radical Radiotherapy of Regionally Localized Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

COMBINED VINBLASTINE AND CHLORAMBUCIL THERAPY OF HODGKIN'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Bulky mediastinal Hodgkin's disease management and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The treatment of stage IIIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The significance of mediastinal involvement in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

An evaluation of long-term survival and treatment complications in children with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Combination chemotherapy in generalized Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in hodgkin's disease. An analysis of long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Childhood Hodgkin's disease in Uganda: a ten year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Growth retardation in children after megavoltage irradiation of the spine.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Treatment of stage IIIA Hodgkin's disease: Is radiotherapy alone adequate?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

EVA treatment for recurrent or unresponsive Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Chemotherapy and irradiation in childhood Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Alternating drug combinations in the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

MVPP chemotherapy regimen for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic groups for management of localized Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Hodgkin's disease, stages I and II.Relationship of recurrence to size of disease, radiation dose, and number of sites involved

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Radiotherapy in the treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The management of stage IIIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

A multivariate analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Prognostic factors in Hodgkin's disease with special reference to age

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Long-term results of treatment of children and adolescents with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980288-4

7 January 2021

10.1016/S0950-3536(05)80288-4

Identifiers

DOI

1 reference

22 August 2017

1 reference